399 related articles for article (PubMed ID: 31662825)
1. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism.
Ullah F; Song J; Rojas Hernandez CM; Kroll MH; Escalante CP; Toale KM
Oncologist; 2023 Nov; 28(11):e1005-e1016. PubMed ID: 37310796
[TBL] [Abstract][Full Text] [Related]
3. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI; Caroti KS; Abdelgawwad K; Psaroudakis G; Fatoba S; Rivera M; Schaefer B; Brobert G; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Brescia C; Cohen AT
JACC CardioOncol; 2023 Apr; 5(2):189-200. PubMed ID: 37144109
[TBL] [Abstract][Full Text] [Related]
8. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
Ross JA; Miller M; Hernandez CR
Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
[TBL] [Abstract][Full Text] [Related]
9. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis.
Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P
Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
Bhalla V; Abdel-Latif A; Bhalla M; Ziada K; Williams MV; Smyth SS
Am J Cardiol; 2018 Oct; 122(7):1236-1243. PubMed ID: 30082040
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
15. Drug Use Evaluation of Direct Oral Anticoagulants (DOACs) in Patients With Advanced Cirrhosis.
Jarboe L; Dadlani A; Bandikatla S; Wade R; Barve A
Cureus; 2022 Apr; 14(4):e24029. PubMed ID: 35547458
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation prescribing patterns in patients with cancer.
Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Nicklaus MD; Ludwig SL; Kettle JK
J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
[TBL] [Abstract][Full Text] [Related]
19. Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up.
Laganà A; Assanto GM; Masucci C; Passucci M; Donzelli L; Serrao A; Baldacci E; Santoro C; Chistolini A
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024020. PubMed ID: 38468835
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]